Table 3.
Adverse events in the three treatment groups
| Variable | NT | CS | CS+A | Total | P Value |
|---|---|---|---|---|---|
| Patients, n | 43 | 171 | 111 | 325 | |
| Patients with adverse events | 0 | 11 (6.4) | 23 (20.7) | 34 (10.5) | <0.001a |
| Infections | 0 | 5 (2.9) | 5 (4.5) | 10 (3.0) | 0.39 |
| Diabetes | 0 | 3 (1.7) | 2 (1.8) | 5 (1.5) | |
| Hypertension | 0 | 2 (1.2) | 1 (0.9) | 3 (0.9) | |
| Hepatotoxicity | 0 | 0 | 6 (5.4) | 5 (1.5) | |
| Leukopenia | 0 | 0 | 4 (3.6) | 4 (1.2) | |
| Gastrointestinal symptoms | 0 | 0 | 3 (2.7) | 3 (0.9) | |
| Bleeding due to ulcerative esophagitis | 0 | 0 | 1 (0.9) | 1 (0.3) | |
| Myalgia | 0 | 1 (0.7) | 0 | 1 (0.3) | |
| Depression | 0 | 0 | 1 (0.9) | 1 (0.3) |
Unless otherwise stated values are number (percentage). NT, no treatment; CS, corticosteroids; CS+A, corticosteroids plus azathioprine.
a
NT versus CS alone: P=0.13; no treatment versus CS+A: P<0.001; CS alone versus CS+A: P=0.001.